Evaluation of a formula for individual dosage of nedaplatin based on renal function

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 3, 2012, Pages 599-603

  Sato, Shinya ^a   Fujiwara, Hiroyuki ^b   Oishi, Tetsuro ^a   Shimada, Muneaki ^a   Machida, Shizuo ^b   Takei, Yuji ^b   Itamochi, Hiroaki ^a   Suzuki, Mitsuaki ^b   Kigawa, Junzo ^a  

^a TOTTORI UNIVERSITY   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

AUC; Formula; Nedaplatin; Renal function

Indexed keywords

IRINOTECAN; NEDAPLATIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DRUG CLEARANCE; FEMALE; HUMAN; ISHIBASHI FORMULA; KIDNEY FUNCTION; OVARY CANCER; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; UTERINE CERVIX CANCER;

ADULT; AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BLOOD PLATELETS; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; KIDNEY; KIDNEY FUNCTION TESTS; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, THEORETICAL; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PLATELET COUNT; PREDICTIVE VALUE OF TESTS; UTERINE CERVICAL NEOPLASMS;

EID: 84859764381     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1739-0     Document Type: Article

References (23)

1. Niioka T, Uno T, Yasui-Furukori N, Takahata T, Shimizu M, Sugawara K, Tateishi T (2007) Pharmacokinetics of low-dose nedaplatin and validation of AUC prediction in patients with non-small-cell lung carcinoma. Cancer Chemother Pharmacol 59:575-580 (Pubitemid 46295121)
2. Koenuma M, Kasai H, Uchida N, Takeda Y, Shiratori O, Muraoka Y, Totani T (1995) Antitumor activity of a new platinum complex, nedaplatin. Clin Rep 29:3213-3222
3. Weiss RB, Christian MC (1993) New cispaltin analogue in development. Drugs 46:360-377
4. Inuyama Y, Miyake H, Horiuchi M, Hayasaki K, Komiyama S, Ota K (1992) An early phase II clinical study of cis-diammine glycolato platinum, 254-s, for head and neck cancers. Jpn J Cancer Chemother 19:863-869
5. Inuyama Y, Hirosato M, Horiuchi M, Hayasaki K, Komiyama S, Ota K (1992) A late phase II clinical study of cis-diammine glycolato platinum, 254-s, for head and neck cancers. Jpn J Cancer Chemother 19:871-877
6. Furuse K, Fukuoka M, Kurita Y, Ariyoshi Y, Niitani H, Yoneda S, Fujii M, Hasegawa K, Nishiwaki Y, Tamura M, Kimura I, Inoue S, Oshima S, Kusume K, Sugimoto K (1992) A phase II clinical study of cis-diammine glycolato platinum, 254-S, for plimary lung cancer. Jpn J Cancer Chemother 19:879-884
7. Taguchi T, Wakui A, Nabeya K, Kurihara M, Isono K, Kakegawa T, Ota K (1992) A phase II clinical study of cis-diammine glycolato platinum, 254-S, for gastrointestinal cancers. Jpn J Cancer Chemother 19:483-488
8. Akaza H, Togashi M, Nishio Y, Miki T, Kotake T, Matsumura Y, Yoshida O, Aso Y (1992) Phase II study of cis-diammine (glycolato) platinum, 254-S, in patients with advanced germ-cell testicular cancer, prostatic cancer, and transitional-cell carcinoma of the urinary tract. 254-S urological cancer. Cancer Chemothe Pharmacol 31:187-192
9. Noda K, Ikeda M, Yakushiji M, Nishimura H, Terashima Y, Sasaki H, Hata T, Kuramoto H, Tanaka K, Takahashi T, Hirabayashi K, Yamabe T, Hatae M (1992) A phase II clinical study of cis-diammine glycolato platinum, 254-S, for cervical cancer of the uterus. Jpn J Cancer Chemother 19:885-892
10. Sugiyama T, Yakushiji M, Noda K, Ikeda M, Kudoh R, Yajima A, Tomoda Y, Terashima Y, Takeuchi S, Hiura M, Saji F, Takahashi T, Umesaki N, Sato S, Hatae M, Ohashi Y (2000) Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer. Oncol 58:31-37 (Pubitemid 30045307)
11. Machida S, Ohwada M, Fujiwara H, Konno R, Takano M, Kita T, Kikuchi Y, Komiyama S, Mikami M, Suzuki M (2003) Phase I study of combination chemothearpy using irinotecan hydrochloride and nedaplatin for advanced or recurrent cervical cancer. Oncology 65:102-107 (Pubitemid 37025968)
12. Sugiyama T, Yakushiji M, Kamura T, Ikeda M, Umesaki N, Hasegawa K, Ishikawa M, Saji F, Hiura M, Takahashi T, Sato S, Oshiai K, Kikkawa F, Takeuchi S, Ohashi Y, Noda K, Japan CPT-11Study Group (2003) Irinotecan (CPT-11) and cisplatin as first line chemotherapy for advanced ovarian cancer. Oncology 63:16-22
13. Matsumura M, Takeshima N, Ota T, Omatsu K, Sakamoto K, Kawamata Y, Umayahara K, Tanaka H, Akiyama F, Takizawa K (2010) Neoadjuvant chemoteharpy followed by radical hysterectomy plus postoperative chemotherapy but no radiotherapy for stage IB2-IIB cervical cancer-Irinotecan and platinum chemotherapy. Gynecol Oncol 119:212-216
14. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-1756 (Pubitemid 19272848)
15. Chatelut E, Canal P, Brunner V, Chevreau C, Boneu A, Roche H, Houin G, Bugat R (1995) Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 87:573-580
16. Ota K, Oguma T, Shimamura K (1994) Pharmacokinetics of platinum in cancer patients following intravenous infusion of cis-diammine (glycolate) platinum, 254-S. Anticancer Res 14:1383-1388 (Pubitemid 2125957)
17. Sasaki Y, Tamura T, Taguchi K, Shinka T, Fujiwara Y, Fukuda M, Ohe Y, Bungo M, Horichi N, Niimi S, Minato K, Nakagawa K, Saijyo N (1989) Pharmacokinetics of (glycolato-O, O')-diammine platinum(II), a new platinum derivative, in comparison with cisplatin and carboplatin. Cancer Chemother Pharmacol 23:243-246 (Pubitemid 19093746)
18. Ishibashi T, Yano Y, Oguma T (2002) A formula for predicting optimal dosage of nedaplatin based on renal function in adult cancer patients. Cancer Chemother Pharmacol 50:230-236 (Pubitemid 35013661)
19. Ikeuchi I, Daikatsu K, Fujisawa I, Amano T (1990) Determination of platinum in biological materials by graphic furnace atomic absorption spectorometry. Iyakuhin Kenkyu 21:1082-1087
20. Ishibashi T, Yano Y, Oguma T (2003) Population pharmacokinetics of platinum after nedaplatin administration and model validation in adult patients. Br J Clin Pharmacol 56:205-213 (Pubitemid 36981436)
21. Sheiner LB, Beal SL (1981) Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9:503-512
22. Duffull SB, Robinson BA (1997) Clinical pharmacokinetics and dose optimization of carboplatin. Clin Pharmacokinet 33: 161-183 (Pubitemid 27399545)
23. Ishibashi T, Yano Y, Oguma T (2005) Determination dosage for nedaplatin based on pharmacokinetic and toxycodynamic analysis. Anticancer Res 25:1273-1282